Viridian Therapeutics, Inc. $VRDN Holdings Boosted by Knights of Columbus Asset Advisors LLC

Knights of Columbus Asset Advisors LLC lifted its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 27.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 90,019 shares of the company’s stock after buying an additional 19,466 shares during the quarter. Knights of Columbus Asset Advisors LLC owned approximately 0.08% of Viridian Therapeutics worth $1,853,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Wellington Management Group LLP raised its holdings in Viridian Therapeutics by 1.6% in the second quarter. Wellington Management Group LLP now owns 3,128,362 shares of the company’s stock valued at $57,468,000 after acquiring an additional 49,808 shares in the last quarter. Parkman Healthcare Partners LLC acquired a new position in Viridian Therapeutics during the 2nd quarter worth $25,306,000. Rice Hall James & Associates LLC acquired a new position in Viridian Therapeutics during the 2nd quarter worth $21,601,000. Bank of America Corp DE increased its position in shares of Viridian Therapeutics by 17.5% in the 1st quarter. Bank of America Corp DE now owns 1,163,615 shares of the company’s stock worth $22,760,000 after purchasing an additional 173,498 shares during the last quarter. Finally, Elmind Capital LP bought a new stake in shares of Viridian Therapeutics in the 2nd quarter worth about $18,093,182.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on VRDN shares. Needham & Company LLC upped their target price on shares of Viridian Therapeutics from $34.00 to $38.00 and gave the company a “buy” rating in a research note on Wednesday, November 4th. Leerink Partners lifted their price target on Viridian Therapeutics from $50.00 to $54.00 and gave the stock an “outperform” rating in a research note on Thursday, November 5th. Wells Fargo & Company boosted their price objective on Viridian Therapeutics from $31.00 to $34.00 and gave the company an “overweight” rating in a report on Thursday, November 5th. Wedbush upped their price objective on Viridian Therapeutics from $41.00 to $42.00 and gave the company an “outperform” rating in a research note on Thursday, November 5th. Finally, Royal Bank Of Canada increased their target price on Viridian Therapeutics from $38.00 to $41.00 and gave the stock an “outperform” rating in a report on Thursday, November 5th. Eleven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $41.00.

Insider Activity at Viridian Therapeutics

In other news, insider Jennifer Tousignant sold 14,212 shares of Viridian Therapeutics stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $24.50, for a total value of $348,194.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 2.40% of the company’s stock.

Viridian Therapeutics Stock Performance

Viridian Therapeutics stock opened at $31.25 on Thursday. The company has a market cap of $3.55 billion, a PE ratio of -8.14 and a beta of 1.07. The company has a fifty day moving average price of $22.44 and a two-hundred day moving average price of $21.78. The company has a debt-to-equity ratio of 0.50, a current ratio of 14.46 and a quick ratio of 14.46. Viridian Therapeutics, Inc. has a 12 month low of $13.18 and a 12 month high of $34.29.

Viridian Therapeutics (NASDAQ:VRDN) last released its earnings results on Wednesday, November 4th. The company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($1.02) by $0.21. Viridian Therapeutics had a negative net margin of 1,620.79% and a negative return on equity of 79.67%. The firm had revenue of $25.75 million during the quarter, compared to analyst estimates of $4.72 million. Research analysts expect that Viridian Therapeutics, Inc. will post -3.64 earnings per share for the current year.

Viridian Therapeutics Profile

Viridian Therapeutics is a clinical-stage biopharmaceutical company developing medicines for serious diseases, with a primary focus on thyroid eye disease (TED), an autoimmune condition that can cause inflammation and changes around the eyes. The company’s pipeline includes veligrotug, an investigational antibody that targets the insulin-like growth factor 1 receptor, a pathway involved in TED. Viridian is also developing additional antibody-based candidates intended to offer treatment options, including formulations designed for under-the-skin administration.